Search Results - "McIntyre, KJ"

Abstract P4-16-01: Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Results of a randomized phase II study by Jones, VE, McIntyre, KJ, Paul, D, Wilks, ST, Ondreyco, SM, Sedlacek, SM, Melnyk, AM, Oommen, SP, Wang, Y, O'Shaughnessy, JA

“…Background: Oral stomatitis is a frequent adverse event (AE) associated with mTOR-inhibitor therapy, and can impact adherence. In BOLERO-2, patients (pts) with…”
Get full text

Abstract P1-15-06: Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Preliminary results of a randomized phase II study by Jones, VL, Jensen, LL, McIntyre, KJ, Oommen, SP, Patt, DA, Cortas, TE, Harris, RP, Wilks, ST, Fox, P, O'Shaughnessy, JA

“…Background: Oral stomatitis is a frequent adverse event (AE) associated with mTOR-inhibitor therapy, and can impact treatment adherence. In the BOLERO-2 trial…”
Get full text

Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062 by O'Shaughnessy, J, Koeppen, H, Crockett, M, Lackner, M, Spoerke, JM, Wilson, T, Levin, MK, Pippen, J, Paul, D, Stokoe, C, Blum, J, Holmes, FA, Lindquist, DL, Krekow, L, Vukelja, SJ, Sedlacek, S, Rivera, R, Brooks, RJ, McIntyre, KJ, Schwartz, JE, Jones, S

“…Background: USON 01062 (O’Shaughnessy J, et al. Proc SABCS, 2010, abst S4-2) showed no improvement in the primary endpoint of disease-free survival (DFS)…”
Get full text

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy by Paul, D, Vukelja, SJ, Holmes, FA, Blum, J, McIntyre, KJ, Kumar, AR, Lindquist, DL, Osborne, CR, Sanchez, IJ, Goldschmidt, JH, Wang, Y, Asmar, L, Lee, ME, Wu, N, Logie, K, O'Shaughnessy, J

“…Introduction Dasatinib inhibits the protein tyrosine kinase, Src, which can support the development of bone metastases in patients with ER+ breast cancer. The…”
Get full text

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor by Wright, GL, Blum, J, Krekow, LK, McIntyre, KJ, Wilks, ST, Rabe, AC, Vukelja, SJ, Andersen, JC, Wang, Y, Asmar, L, O'Shaughnessy, J

“…Introduction: Fulvestrant is an effective endocrine therapy in patients with ER+ metastatic breast cancer (MBC) that has become resistant to non-steroidal…”
Get full text

Essential thrombocythemia in young adults by McIntyre, K J, Hoagland, H C, Silverstein, M N, Petitt, R M

“…Essential thrombocythemia is typically a disorder of adults in the sixth or seventh decade of life and is characterized by frequent thrombohemorrhagic…”
Get more information